Skip to main
THC

Tenet Healthcare (THC) Stock Forecast & Price Target

Tenet Healthcare (THC) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 56%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Tenet Healthcare is expected to continue generating strong earnings with projected Adjusted EBITDA estimates of $4.665 billion in 2026, $4.935 billion in 2027, and $5.109 billion in 2028, surpassing its peers in the healthcare services sector. Despite potential concerns about declining HIX volumes and negative sentiment towards hospitals and healthcare services, the company's well-managed capacity to adapt and its favorable capital deployment and return posture make it significantly undervalued and a valuable opportunity for investors.

Bears say

Tenet Healthcare is facing significant headwinds in the form of a reduction in HIX enrollment, which is expected to result in a ~20% decrease in revenue. Additionally, the expiration of ACA subsidies will create a material headwind for the company. There is also a high level of uncertainty around healthcare reform and policy, which could significantly impact the company's funding environment. Although the company's financials have been strong, with a solid EBITDA margin and positive cash flow, the potential for volume pressure and uncertainties surrounding healthcare policies make for a negative outlook on Tenet Healthcare's stock.

Tenet Healthcare (THC) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 56% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenet Healthcare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenet Healthcare (THC) Forecast

Analysts have given Tenet Healthcare (THC) a Buy based on their latest research and market trends.

According to 18 analysts, Tenet Healthcare (THC) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $263.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $263.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenet Healthcare (THC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.